Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (242)	6/11/2009 12:50:11 PM
From: A.J. Mullen	Respond to of 276

Yes, I'm sure you're right. I have no problem with a high-priced introduction - it will enable them to work up to high volumes. The value will be in interpretation the statistical evaluation. It would be useful if different companies produced rival programs for analysing the data. I wonder why they will deliver the data loaded on a dedicated machine. Is that simply marketing? A web-based system seems more straight-forward, but maybe there will be a greater sense of privacy with individuals holding their data. But if everyone holds their own data, then there won't be the opportunity to learn from their case-histories in the way 23andme plans. Ashley Ashley